Medicines and Healthcare products Regulatory Agency

gov.uk Imported from official source

UK medicines and medical devices regulator; recalls and safety alerts.

Publications 148

  1. New MHRA service to support medicines innovation and strengthen UK manufacturing  

    AdvanceGxP will give developers earlier practical support for advanced manufacturing technologies, accelerating patient access to innovative medicines while strengthening UK manufacturing. 

    Alert Safety
  2. MHRA AdvanceGxP service: building compliance into innovation earlier

    A new MHRA service being developed to help organisations working on novel medicines technologies consider Good Practice requirements earlier.

    Alert Safety
  3. Field Safety Notices: 9 to 13 November 2026

    List of Field Safety Notices from 9 to 13 November 2026.

    Alert Safety
  4. MHRA launches new programme to tackle evidence gaps on women’s health 

    Women’s Health Programme aims to support innovation in women’s health and better understand how the risks and benefits of medicines and medical devices may differ for women.

    Alert Safety
  5. Corporate report: MHRA Women’s Health Programme 2026-2030

    The Women’s Health Programme supports better evidence and regulation of medicines and medical devices to improve health outcomes for women.

    Alert Safety
  6. MHRA: services during Microsoft outage

    We are experiencing problems sending and receiving emails.

  7. Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48

    Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12. mg” instead...

    Alert Safety
  8. MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer

    The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC).

    Alert Safety
  9. Field Safety Notices: 2 to 6 November 2026

    List of Field Safety Notices from 2 to 6 October 2026.

    Alert Safety 2 versions
  10. Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway 

    Three innovative medicines with the potential to meet unmet needs in lung cancer, Huntington’s disease and Alzheimer’s disease have been given Innovation Passports, the Medicines and Healthcare pro...

    Alert Safety
  11. Standard: Periods of Data and Market Exclusivity for UK Reference Medicinal Products

    UK reference medicinal products authorised in the period 2014 – 2021 and their associated dates of expiry of data protection, marketing exclusivity.

    Alert Safety
  12. Guidance: Guidance on bringing software as a medical device to market

    Overview of the key regulatory steps and guidance to consider when bringing software as a medical device (SaMD) to market in Great Britain and Northern Ireland.

    Alert Safety
  13. MHRA sets out approach to strengthen patient and public involvement and engagement in medicines and medical device regulation 

    New plan will broaden participation and make clearer how patient experience informs regulatory decisions, safety and innovation

    Alert Safety
  14. Corporate report: Patient and Public Involvement 
and Engagement Plan 2026-2030

    This plan sets out the MHRA’s approach to place meaningful involvement and engagement at the heart of the agency’s work for 2026-2030.

    Alert Safety
  15. Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat

    There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and as...

    Alert Safety
  16. Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/47

    Aspire Pharma Ltd is recalling specific batches of Tropicamide 1% Eye Drops, solution in single dose containers 0.5ml x 20, due to them being labelled with the incorrect expiry date. The correct ex...

    Alert Safety
  17. Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46

    Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension.

    Alert Safety
  18. Digital Mental Health Technologies (DMHT): Phase 1 evaluation survey

    The MHRA and the NICE are seeking feedback on the resources developed through the Wellcome Digital Mental Health Technologies (DMHT) programme.

    Alert
  19. MHRA guidance on its assessment of non-clinical data generated outside OECD system 

    MHRA issues new guidance on its approach to clinical trial applications that rely on non-clinical safety data generated outside the OECD Mutual Acceptance of Data system.  

    Alert Safety
  20. Use of non-OECD MAD non-clinical data in support of UK clinical trial authorisation applications

    MHRA guidance on the use of non-clinical data generated outside the OECD MAD framework in support of UK Clinical Trial Authorisation applications.

    Alert Safety
  21. Field Safety Notices: 26 to 30 October 2026

    List of Field Safety Notices from 26 to 30 October 2026.

    Alert Safety
  22. Decision: Advertising investigations: October 2026

    Decisions made by MHRA on adverts reported to have breached the legislation on advertising medicines.

    Alert Safety
  23. Clinical trials for medicines: Inclusion and Diversity Plan pilot findings published

    The Health Research Authority (HRA) has published the findings from its pilot on researchers and sponsors of clinical trials and clinical investigations developing and submitting an Inclusion and D...

    Alert Safety
  24. MHRA launches patient safety essay competition for MedSafetyWeek

    The MHRA reminds patients, parents, carers and healthcare professionals to report suspected side effects through the Yellow Card scheme for MedSafetyWeek 2026.

    Alert Safety
  25. Triheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disorders

    MHRA approves triheptanoin to treat adult and paediatric patients with a group of rare inherited disorders.

    Alert Safety
  26. MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders

    Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK aut...

    Alert Safety
  27. Class 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45

    Accord-UK Ltd is recalling one batch of Lercanidipine Hydrochloride 10mg Tablets due to a packaging mix-up involving the incorrect strength.

    Alert Safety
  28. Class 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44

    Advanz Pharma Limited are recalling specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure.

    Alert Safety
  29. Field Safety Notices: 19 to 23 October 2026

    List of Field Safety Notices from 19 to 23 October 2026.

    Alert Safety
  30. MHRA Safety Roundup: October 2026

    Summary of the latest safety advice for medicines and medical device users

    Alert Safety
  31. New MHRA research puts needle-free Strep A vaccine within reach

    Pioneering study by MHRA scientists advances innovative approach to vaccination and promise of vaccine against Strep A.

    Alert Safety
  32. #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app

    The annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. This year's theme is ‘S...

    Alert Safety
  33. Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43

    Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel.

    Alert Safety
  34. Government confirms indefinite recognition of CE marked medical devices

    Patients across Great Britain will have continued access to medical devices and in vitro diagnostic devices (IVDs) already approved for the EU market.

    Alert Safety
  35. IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review

    Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK ...

    Alert Safety
  36. MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome

    The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 October 2026, authorised plozasiran (Redemplo)

    Alert Safety
  37. UK regulator brings new AI and MedTech agenda to AdvaMed

    UK’s Medicines and Healthcare products Regulatory Agency (MHRA) sets out its next phase of MedTech and AI regulation to US industry leaders at AdvaMed 2026.

    Alert AI
  38. Field Safety Notices: 5 to 9 October 2026

    List of Field Safety Notices from 5 to 9 October 2026.

    Alert Safety
  39. Field Safety Notices: 12 to 16 October 2026

    List of Field Safety Notices from 12 to 16 October 2026.

    Alert Safety 2 versions
  40. Consultation on schools holding Adrenaline Nasal Sprays for anaphylaxis

    The MHRA are seeking feedback on proposals to amend the Human Medicines Regulations 2012 to allow schools to hold Adrenaline Nasal Sprays to treat anaphylaxis in pupils.

    Alert Safety
  41. MHRA consults on proposals to allow schools to keep spare adrenaline nasal sprays on site

    The MHRA is now consulting on proposals that would give schools an additional option to support children at risk of life-threatening allergic reactions.

    Alert Safety
  42. Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police

    Fake weight loss medicines worth approximately £2 million were seized last night in a raid executed by the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police.

    Alert Safety
  43. MHRA introduces new safeguards to strengthen antidepressant safety information following major review

    New and updated patient information for antidepressant medicines to be introduced following an extensive review involving patients, families and independent experts.

    Alert Safety
  44. Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction

    New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medic...

    Alert Safety
  45. Research: Antidepressants – updated safety communications

    Public Assessment Report on the review of antidepressants. How the risks of suicidal thoughts and behaviours and sexual dysfunction (where symptoms continue after stopping treatment), are communica...

    Alert Safety
  46. Guidance: MHRA Strategy to 2030: What it means for you

    A series of explainers to help you understand the parts of the MHRA Strategy to 2030 most relevant to you, and what they mean in practice.

    Alert Safety
  47. MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines

    The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients...

    Alert AI Safety
  48. Corporate report: MHRA Strategy 2030

    How the MHRA Strategy to 2030 sets out to deliver health and prosperity for all, through scientific excellence.

    Alert Safety
  49. MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes

    The new treatment option is administered once weekly, potentially reducing the number of injections from up to 365 a year to 52 for some adults with type 2 diabetes.

    Alert Safety

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.